New approach tests drugs to help immune system fight prostate cancer before surgery
NCT ID NCT06888102
Summary
This early study is testing whether giving epigenetic drugs before prostate removal surgery is safe and can make prostate cancer tumors more recognizable to the patient's own immune system. It will involve 20 men with high-risk prostate cancer who are already scheduled for surgery. The main goal is to check safety and see if these drugs cause measurable biological changes in the tumor tissue that is removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at SOCC
RECRUITINGLos Angeles, California, 90048, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.